The Life Without Limits campaign will include digital content, events, and community outreach. Image credit: Shutterstock

Medtronic Diabetes has entered a partnership with professional tennis player Alexander Zverev to launch “Life Without Limits” – a global awareness campaign aimed at highlighting how diabetes technology can help people with type 1 diabetes to live active and independent lives.

Zverev, who was diagnosed with type 1 diabetes at age 4, is currently one of the top-ranked players on the ATP Tour and an Olympic gold medalist. The Grand Slam finalist has candidly shared the difficulties of managing diabetes as a professional athlete, including the need to take insulin during high-stake, competitive matches.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Through the partnership, Zverev hopes to motivate others living with type 1 diabetes by demonstrating what can be achieved with diabetes technologies such as automated insulin delivery systems.

“Becoming a professional tennis player was always my dream,” said Zverev. “Early on, I was told that competing at the highest level with diabetes was impossible – but my family and I refused to accept that. That’s why I’m partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want.”

Medtronic Diabetes will become MiniMed

The partnership comes at a pivotal time for Medtronic’s California-based diabetes business. In May, the company announced plans to spin off the division into a new standalone entity named MiniMed – a name that harkens back to its identity prior to Medtronic’s 2001 acquisition.

Medtronic says the move aims to establish an “independent, scaled leader in diabetes”, with the separation expected to be completed within 18 months.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In the company’s FY 2025 results, the diabetes business accounted for 8% of total company revenues, reaching around $2.75 bn – a 10.7% year-over-year increase. However, recent performance was impacted by a 2024 FDA Class I recall of the MiniMed insulin pump system, which dented consumer confidence amid rising market competition.

According to GlobalData analysis, Medtronic held approximately 6% of the US insulin delivery market and 7.3% of the glucose monitoring segment in 2024.

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now